Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-261 in moderate to severe active Crohn's disease
NCT07078994Phase 2Recruiting
- Sponsor
- BIOCAD
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of BCD-261 in Crohn's disease, sponsored by BIOCAD. Started Aug 2025; status: recruiting.
02
Drugs
BCD-261
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07078994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07078994.